Achaogen Stock Price, News & Analysis (NASDAQ:AKAO)

$11.95 0.26 (2.22 %)
(As of 11/17/2017 02:48 PM ET)
Previous Close$11.69
Today's Range$11.68 - $12.18
52-Week Range$4.67 - $27.79
Volume711,300 shs
Average Volume860,179 shs
Market Capitalization$502.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:AKAO
  • CUSIP: N/A
  • Web: www.achaogen.com
Debt:
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 6.99%
  • Quick Ratio: 6.99%
Sales & Book Value:
  • Annual Sales: $41.77 million
  • Price / Sales: 12.13
  • Book Value: $3.62 per share
  • Price / Book: 3.30
Profitability:
  • Trailing EPS: ($3.36)
  • Net Income: ($71,220,000.00)
  • Net Margins: -593.61%
  • Return on Equity: -80.44%
  • Return on Assets: -51.17%
Misc:
  • Employees: 106
  • Outstanding Shares: 42,390,000
 
Frequently Asked Questions for Achaogen (NASDAQ:AKAO)

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen, Inc. (NASDAQ:AKAO) announced its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.13. The biopharmaceutical company earned $0.58 million during the quarter, compared to analysts' expectations of $2.09 million. Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The firm's revenue was down 96.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.41) earnings per share. View Achaogen's Earnings History.

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2017?

9 Wall Street analysts have issued 12 month target prices for Achaogen's stock. Their forecasts range from $17.00 to $29.00. On average, they expect Achaogen's stock price to reach $25.63 in the next year. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (11/14/2017)
  • 2. Mizuho analysts commented, "We believe the recent price pullback from 52-week highs presents a buying opportunity especially considering Plazomicin represents meaningful advances in the aminoglycoside class with survival benefits ." (11/9/2017)
  • 3. Cowen and Company analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
  • 4. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
  • 5. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

  • Bryan E. Roberts Ph.D., Independent Chairman of the Board (Age 50)
  • Blake Wise, President, Chief Operating Officer (Age 46)
  • Kenneth J. Hillan, Chief Executive Officer, Director (Age 56)
  • Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (Age 42)
  • Lee Swem Ph.D., Senior Vice President, Chief Scientific Officer (Age 41)
  • Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy (Age 35)
  • Gary Loeb, General Counsel (Age 47)
  • Janet Dorling, Chief Commercial Officer
  • Karen Bernstein Ph.D., Independent Director
  • John C. Doyle, Independent Director (Age 48)

Who owns Achaogen stock?

Achaogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (5.32%), TimesSquare Capital Management LLC (3.22%), Artal Group S.A. (0.59%), Candriam Luxembourg S.C.A. (0.43%), University of Notre Dame DU Lac (0.37%) and Bank of New York Mellon Corp (0.33%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Who sold Achaogen stock? Who is selling Achaogen stock?

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Iguana Healthcare Management LLC, Marcus Capital LLC, Candriam Luxembourg S.C.A., New York State Common Retirement Fund, TD Asset Management Inc. and Russell Investments Group Ltd.. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Insider Buying and Selling for Achaogen.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., TimesSquare Capital Management LLC, Schwab Charles Investment Management Inc., University of Notre Dame DU Lac, Artal Group S.A., Hikari Power Ltd, First Midwest Bank Trust Division and Sei Investments Co.. View Insider Buying and Selling for Achaogen.

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of Achaogen stock can currently be purchased for approximately $11.95.

How big of a company is Achaogen?

Achaogen has a market capitalization of $502.36 million and generates $41.77 million in revenue each year. The biopharmaceutical company earns ($71,220,000.00) in net income (profit) each year or ($3.36) on an earnings per share basis. Achaogen employs 106 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 7000 Shoreline Ct Ste 371, SOUTH SAN FRANCISCO, CA 94080-7603, United States. The biopharmaceutical company can be reached via phone at +1-650-8003636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Achaogen (NASDAQ:AKAO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $25.63 (114.44% upside)
Consensus Price Target History for Achaogen (NASDAQ:AKAO)
Price Target History for Achaogen (NASDAQ:AKAO)
Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Stifel NicolausLower Price TargetBuy -> Buy$30.00 -> $27.00N/AView Rating Details
11/9/2017HC WainwrightReiterated RatingPositive -> Buy$25.00N/AView Rating Details
11/9/2017MizuhoReiterated RatingBuy$28.00N/AView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$17.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingOutperform -> Outperform$28.00 -> $22.00N/AView Rating Details
5/15/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
4/24/2017WedbushReiterated RatingOutperform$28.00HighView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
9/26/2016SunTrust Banks, Inc.Reiterated RatingBuy$10.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Achaogen (NASDAQ:AKAO)
Earnings by Quarter for Achaogen (NASDAQ:AKAO)
Earnings History by Quarter for Achaogen (NASDAQ AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3($0.72)($0.85)$2.09 million$0.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achaogen (NASDAQ:AKAO)
2017 EPS Consensus Estimate: ($2.65)
2018 EPS Consensus Estimate: ($3.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.48)($0.54)
Q2 20174($0.71)($0.58)($0.66)
Q3 20174($0.88)($0.62)($0.72)
Q4 20174($0.99)($0.59)($0.74)
Q1 20183($1.03)($0.63)($0.80)
Q2 20183($0.91)($0.69)($0.78)
Q3 20184($0.90)($0.70)($0.80)
Q4 20183($0.91)($0.61)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Achaogen (NASDAQ AKAO)
Insider Ownership Percentage: 8.36%
Institutional Ownership Percentage: 83.81%
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)
Insider Trades by Quarter for Achaogen (NASDAQ AKAO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2017Blake WiseCOOSell3,576$15.99$57,180.24View SEC Filing  
9/26/2017Gary LoebGeneral CounselSell1,146$15.99$18,324.54View SEC Filing  
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Achaogen (NASDAQ:AKAO)
Latest Headlines for Achaogen (NASDAQ AKAO)
Source:
DateHeadline
Achaogen, Inc. (AKAO) Cut to Sell at Zacks Investment ResearchAchaogen, Inc. (AKAO) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 14 at 8:28 PM
Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $990,000.00Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $990,000.00
www.americanbankingnews.com - November 14 at 9:58 AM
Research Analysts Set Expectations for Achaogen, Inc.s Q3 2018 Earnings (AKAO)Research Analysts Set Expectations for Achaogen, Inc.'s Q3 2018 Earnings (AKAO)
www.americanbankingnews.com - November 13 at 7:54 AM
Q4 2017 EPS Estimates for Achaogen, Inc. Cut by Analyst (AKAO)Q4 2017 EPS Estimates for Achaogen, Inc. Cut by Analyst (AKAO)
www.americanbankingnews.com - November 13 at 5:16 AM
William Blair Weighs in on Achaogen, Inc.s Q4 2017 Earnings (AKAO)William Blair Weighs in on Achaogen, Inc.'s Q4 2017 Earnings (AKAO)
www.americanbankingnews.com - November 13 at 5:16 AM
Achaogen, Inc. Forecasted to Post FY2020 Earnings of ($0.18) Per Share (AKAO)Achaogen, Inc. Forecasted to Post FY2020 Earnings of ($0.18) Per Share (AKAO)
www.americanbankingnews.com - November 10 at 7:46 PM
Achaogen, Inc. (AKAO) Issues  Earnings ResultsAchaogen, Inc. (AKAO) Issues Earnings Results
www.americanbankingnews.com - November 10 at 8:23 AM
Achaogen, Inc. (AKAO) Announces Quarterly  Earnings Results, Misses Expectations By $0.13 EPSAchaogen, Inc. (AKAO) Announces Quarterly Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - November 9 at 2:27 PM
HC Wainwright Lowers Achaogen, Inc. (AKAO) Price Target to $25.00HC Wainwright Lowers Achaogen, Inc. (AKAO) Price Target to $25.00
www.americanbankingnews.com - November 9 at 7:58 AM
Achaogens (AKAO) CEO Kenneth Hillan on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAchaogen's (AKAO) CEO Kenneth Hillan on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 4:04 AM
Achaogen to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)Achaogen to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 7 at 2:34 AM
Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8,Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8,
www.nasdaq.com - October 30 at 4:32 PM
Achaogen, Inc. (AKAO) Given Buy Rating at MizuhoAchaogen, Inc. (AKAO) Given Buy Rating at Mizuho
www.americanbankingnews.com - October 30 at 6:16 AM
Can Achaogen Turn It Around After A Long Slide? - Seeking AlphaCan Achaogen Turn It Around After A Long Slide? - Seeking Alpha
seekingalpha.com - October 27 at 5:48 PM
Achaogen (AKAO) Reports FDA Submission of Plazomicin New Drug Application - StreetInsider.comAchaogen (AKAO) Reports FDA Submission of Plazomicin New Drug Application - StreetInsider.com
www.streetinsider.com - October 26 at 11:09 AM
 Analysts Expect Achaogen, Inc. (AKAO) Will Post Quarterly Sales of $1.69 Million Analysts Expect Achaogen, Inc. (AKAO) Will Post Quarterly Sales of $1.69 Million
www.americanbankingnews.com - October 25 at 7:54 PM
FY2019 EPS Estimates for Achaogen, Inc. Lowered by Leerink Swann (AKAO)FY2019 EPS Estimates for Achaogen, Inc. Lowered by Leerink Swann (AKAO)
www.americanbankingnews.com - October 12 at 4:18 PM
Achaogen, Inc. to Post Q3 2017 Earnings of ($0.72) Per Share, William Blair Forecasts (AKAO)Achaogen, Inc. to Post Q3 2017 Earnings of ($0.72) Per Share, William Blair Forecasts (AKAO)
www.americanbankingnews.com - October 11 at 8:00 AM
Achaogen (AKAO) versus Its Peers Critical SurveyAchaogen (AKAO) versus Its Peers Critical Survey
www.americanbankingnews.com - October 10 at 4:28 AM
Achaogens (AKAO) Outperform Rating Reaffirmed at Leerink SwannAchaogen's (AKAO) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - October 9 at 10:02 AM
Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.69 MillionAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.69 Million
www.americanbankingnews.com - October 6 at 8:04 AM
Achaogen (AKAO) versus Reata Pharmaceuticals (RETA) Financial ReviewAchaogen (AKAO) versus Reata Pharmaceuticals (RETA) Financial Review
www.americanbankingnews.com - October 4 at 2:54 PM
Achaogen, Inc. (AKAO) Given Consensus Rating of "Buy" by AnalystsAchaogen, Inc. (AKAO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - October 4 at 6:52 AM
Contrasting Achaogen (AKAO) & The CompetitionContrasting Achaogen (AKAO) & The Competition
www.americanbankingnews.com - October 2 at 12:22 AM
Achaogen, Inc. (AKAO) Earns Buy Rating from MizuhoAchaogen, Inc. (AKAO) Earns Buy Rating from Mizuho
www.americanbankingnews.com - September 29 at 2:06 PM
Insider Selling: Achaogen, Inc. (AKAO) General Counsel Sells 1,146 Shares of StockInsider Selling: Achaogen, Inc. (AKAO) General Counsel Sells 1,146 Shares of Stock
www.americanbankingnews.com - September 28 at 8:12 PM
Insider Selling: Achaogen, Inc. (AKAO) COO Sells 3,576 Shares of StockInsider Selling: Achaogen, Inc. (AKAO) COO Sells 3,576 Shares of Stock
www.americanbankingnews.com - September 28 at 7:48 PM
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017 - GlobeNewswire (press release)Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017 - GlobeNewswire (press release)
globenewswire.com - September 28 at 4:16 PM
Achaogen (AKAO) Secures Max $18M Contract from BARDA for Support Development of Orally-Administered ... - StreetInsider.comAchaogen (AKAO) Secures Max $18M Contract from BARDA for Support Development of Orally-Administered ... - StreetInsider.com
www.streetinsider.com - September 28 at 4:16 PM
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
www.nasdaq.com - September 27 at 8:11 PM
Achaogen Adds Liz Bhatt as Chief Business Officer - GlobeNewswire (press release)Achaogen Adds Liz Bhatt as Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 20 at 3:36 PM
Achaogen (AKAO) Appoints Liz Bhatt as Chief Business Officer - StreetInsider.comAchaogen (AKAO) Appoints Liz Bhatt as Chief Business Officer - StreetInsider.com
www.streetinsider.com - September 18 at 9:05 PM
ETFs with exposure to Achaogen, Inc. : September 18, 2017ETFs with exposure to Achaogen, Inc. : September 18, 2017
finance.yahoo.com - September 18 at 9:05 PM
-$0.72 Earnings Per Share Expected for Achaogen, Inc. (AKAO) This Quarter-$0.72 Earnings Per Share Expected for Achaogen, Inc. (AKAO) This Quarter
www.americanbankingnews.com - September 15 at 8:44 PM
Achaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by BrokeragesAchaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 6:26 AM
Achaogen, Inc. (AKAO) Now Covered by Analysts at MizuhoAchaogen, Inc. (AKAO) Now Covered by Analysts at Mizuho
www.americanbankingnews.com - September 6 at 5:18 PM
Achaogen, Inc. :AKAO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017Achaogen, Inc. :AKAO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 4:56 PM
Achaogen Announces New Employment Inducement Grants - GlobeNewswire (press release)Achaogen Announces New Employment Inducement Grants - GlobeNewswire (press release)
globenewswire.com - August 21 at 8:54 PM
Achaogen, Inc. (AKAO) Given Average Rating of "Buy" by BrokeragesAchaogen, Inc. (AKAO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:50 AM
Achaogen to Present at the Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)Achaogen to Present at the Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 8 at 8:42 PM
Achaogen to Present at the Wedbush PacGrow Healthcare ConferenceAchaogen to Present at the Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 8:42 PM
Stifel Nicolaus Reaffirms Buy Rating for Achaogen, Inc. (NASDAQ:AKAO)Stifel Nicolaus Reaffirms Buy Rating for Achaogen, Inc. (NASDAQ:AKAO)
www.americanbankingnews.com - August 5 at 11:34 AM
BIOVERATIV INC (BIVV) vs. Achaogen (NASDAQ:AKAO) Head-To-Head ReviewBIOVERATIV INC (BIVV) vs. Achaogen (NASDAQ:AKAO) Head-To-Head Review
www.americanbankingnews.com - August 5 at 8:30 AM
Achaogen, Inc. (NASDAQ:AKAO) Releases  Earnings ResultsAchaogen, Inc. (NASDAQ:AKAO) Releases Earnings Results
www.americanbankingnews.com - August 4 at 4:20 PM
Edited Transcript of AKAO earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of AKAO earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 4:01 PM
Achaogen reports 2Q lossAchaogen reports 2Q loss
finance.yahoo.com - August 3 at 9:56 PM
Achaogen, Inc. – Value Analysis (NASDAQ:AKAO) : August 4, 2017Achaogen, Inc. – Value Analysis (NASDAQ:AKAO) : August 4, 2017
finance.yahoo.com - August 3 at 9:56 PM
Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 3 at 4:54 PM
Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateAchaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 3 at 4:54 PM
Achaogen, Inc. (NASDAQ:AKAO) to Release Earnings on MondayAchaogen, Inc. (NASDAQ:AKAO) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM

Social Media

Financials

Chart

Achaogen (NASDAQ AKAO) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.